top of page

Acute Coronary Syndrome: Oral P2Y12 Inhibitors - #MEDSHED

Writer's picture: Mark Nguyen, PharmD, BCEMPMark Nguyen, PharmD, BCEMP
Apr 4, 20241 min read

Updated: Apr 8, 2024

Welcome to the #MEDSHED! Needing a brief, concise review of clinical pharmacotherapy and disease management? Direct links of reference to content discussed? Look no further than the #MEDSHED series based on infographics and carousel presentations!
 


 

💟 ACS: Oral P2Y12 Inhibitors - #MEDSHED



💊 P2Y12 inhibitors are a part of standard therapy pre-PCI. They're general mechanism is to inhibit the P2Y12 receptor on platelets, resulting in a reduction in platelet aggregation.



📭 Three oral agents that are utilized include clopidogrel, ticagrelor, and prasugrel. Clopidogrel has been the most historically used as ticagrelor and prasugrel are newer agents. The more novel P2Y12 inhibitors provide favorable pharmacokinetics compared to clopidogrel.



🌐 However, there are several considerations to keep in mind when selecting specific agents per patient parameters. Clopidogrel has a slow onset of action compared to the other agents and extensively metabolized by CYP2C19. Ticagrelor has been associated with therapy discontinuation due to dypsnea and bradyarrhythmias. With prasugrel, be mindful that it is contraindicated in patient's with a history of stroke or TIA secondary to increased risk of bleeding.



✹ Let me know what questions you have in the comments!



Website: www.pharmwyze.comShop: www.pharmwyze.com/shop







PHARMWYZE SITREP Newsletter: https://www.pharmwyze.com/sitrepnewsletter



Not medical advice. Educational purposes only. No relationships to report.



 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
bottom of page